

Access to Vaccines The powerful role for manufacturers

Dr. Jayasree K. Iyer, Executive Director 26th October 2016



5 billion people have access to medicine 2 billion to go

Availability	Accessibility	Affordability	Acceptability

The Foundation



- Research on, and incentives for, pharmaceutical companies and access to medicine
- Fully independent from pharmaceutical companies
- Multi-stakeholder approach
- 2016: 5th Access to Medicine Index
- 2017: 1st Access to Vaccines Index



Ministry of Foreign Affairs of the Netherlands



Department for International Development BILL& MELINDA GATES foundation



Our model for change

Build consensus

on what to expect from the industry and where incentives and disincentives exist.


Stimulate a "race to do well"

in key access-to-medicine areas, by creating competition on targets and topics.

Diffuse best practices

to share information and new insights into the best approaches for driving change.









access to


FOUNDATION

mentetne

What we do







Access to Vaccines Index



Advancing the debate



Funders



"The companies at the top of the Index want to do more. The ones at the bottom see that and push forward on it."

Bill Gates



Global Health



"The Index is a very important project. What gets measured, gets done."

Dr Margaret Chan

Media



"While progress is uneven, many drug makers are, by and large, making headway. In fact, access is increasingly seen as a necessary business issue."

Wall Street Journal

Pharma Companies



"The Index challenges us to think harder about how we drive innovation and enable access to our products."

Sir Andrew Witty, GSK CEO

Investors




"We are increasingly reviewing corporate approaches to access to medicine as a key strategic consideration."

53 Signatory Investors

What we do



<section-header><section-header><section-header><section-header><section-header><section-header>



Access to Vaccines Index





58 investors – AUM in excess of USD 5.31 trillion

achmea Ď	acliam	Adrian Dominican Sisters	AMPCAPITAL	Amundi	🐝 apg	ASN CBANK	o australianethical
AVIVA	🛞 J. SAFRA SARASIN hearene loos Prote locarg and 1841	BMO Global Asset Management	BNP PARIBAS INVESTMENT PARTNERS	BOSTON COMMON		CANDRIAM	Central Finance Board
Church of Sweden 💠	DANA Investment Advises	DAUGHTERS	deita lloyd Asset Management		edentree Instant management		 ethos
	Henderson	HERMES	CORPORATE CORPORATE RESPONSIBILITY	KEMPEN CAPITAL MANAGEMENT		MERCY Networks in an and	Second Second
Miller Howard			NEI	Nordea	Northwest Coalition for Responsible Investment	Asset Management	Öhman
PAX OP Pax World Mutual Funds	PGGM	Rathbone Greenbank Investments	ROBECO	ROYAL	a Schroders	THE SUTTERS OF SEE FRANCIN OF PHEADERTHIS	SPH
	Standard Life Investments	St.JosephHealth	Stewart Investors		Triodos@investment Management	trusteem 🏹 finance	

access to


FOUNDATION

medicine

What we do







Access to Vaccines Index





Thematic Studies



April 2015 Improving Maternal Health



- Pharma's contribution to MDG 5
- UN Foundation Every Woman, Every Child
- 2 new commitments from companies

September 2015 Vaccine Pipeline Analysis



- Pipeline study for highburden diseases
- Blogpost in GHTC
- Increased investor engagement on company plans

December 2015 On Hepatitis-C




- Access to Hepatitis C treatments
- Landscape study policy recommendations
- Publication in WHO Bulletin

What we do







Access to Vaccines Index





Advancing the debate

access to medicine FOUNDATION














RESPONSIBILITY




Medicines for Malaria Venture

What we do







Access to Vaccines Index




Advancing the debate



DCVMN: Contributing to access





Access to Vaccines Index: A new catalyst for action



- What is the role for vaccine companies in improving access?
- Baseline of companies' access efforts, e.g.:
 - R&D to fill product gaps
 - *Registration in high-need countries*
 - Collaboration to align supply and demand
 - Addressing supply chain issues
- Track progress
- Identify incentives and barriers for the industry
- Share best practices

Building the methodology in 2015







Methodology: Access to Vaccines Index





Scopes

- Preventive vaccines
- 69 diseases
- 107 countries
- 9 companies

Disease scope



WHO position

- Routine immunization schedules
- R&D priority

Stakeholder recommendations

- Maternal immunisation
- Emerging infectious diseases
- Diarrhoeal diseases
- Lower respiratory infections
- Neglected tropical diseases

69 diseases

access to medicine FOUNDATION

DISEASES WITH EXISTING VACCINES

Cholera Denguei Diphtheria Haemophilus influenzae type B (Hib) Human papillomavirus (HPV) Japanese encephalitis Malaria Measles Meningococcal disease Mumps Pandemic influenza Pertussis Plague (Yersinia pestis) Pneumococcal disease Polio Rabies Rotavirus Rubella Seasonal influenza Tetanus Tick-borne encephalitis Tuberculosis Typhoid Varicella Viral hepatitis (A, B, C, E)ⁱⁱⁱ Yellow fever

DISEASES WITHOUT EXISTING VACCINES ON THE MARKET

Adenovirus^{iv} Amoebiasis Balantidiasis Buruli Ulcer Campylobacter enteritis Chagas disease Chikungunya Clostridium difficile Cryptosporidiosis Cytomegalovirus (CMV) Dracunculiasis Ebolavirus Echinococcosis Enterovirus 71 Escherichia coli infections Food-borne trematodiases Giardiasis Group B streptococcus Hantavirus pneumonia Human African trypanosomiasis Human Immunodeficiency virus (HIV)

Human metapneumovirus Human monkeypox Isosporiasis Klebsiella pneumoniae Lassa fever Leishmaniasis Leprosy Lymphatic filariasis Marburg (haemorrhagic) virus Onchocerciasis Parainfluenza Pneumocystis jiroveci Respiratory Syncytial Virus (RSV) Schistosomiasis Severe Acute Respiratory Syndrome (SARS) Shigellosis Soil-transmitted helminthiasis Staphylococcus aureus^v Taeniasis/cysticercosis Trachoma Yaws Yersinia enterocolitica

107 countries

access to medicine FOUNDATION

Legend: Basis for inclusion

- 📕 On Gavi support
- Transitioning from Gavi support
- Not on Gavi support
- Outside country scope

9 companies



List of companies included in the 2017 Access to Vaccines Index – 9 companies

Company	Country	Total revenue 2014	Vaccine revenue 2014
		(bn USD)	(bn USD)
AstraZenecaplc	GBR	26.1	0.295
Daiichi Sankyo Co. Ltd.	JPN	7.6	n/a
GlaxoSmithKline plc	GBR	37.9	5.26
Johnson & Johnson	USA	74.3	n/a
Merck & Co. Inc.	USA	42.2	6.25
Pfizer Inc.	USA	49.6	4.48
Sanofi	FRA	43.1	5.85
Serum Institute of India Ltd.	IND	n/a	n/a
Takeda Pharmaceutical Co. Ltd.	JPN	14.8	0.315

Research Areas



R&D



Affordability



Manufacturing & Supply



A Research & Development





- A.1 R&D investments
- A.2 R&D projects vaccines
- **A.3** R&D projects technologies
- A.4 Facilitating access

B Affordability

access to medicine Foundation



- **B.1** Needs-based pricing
- **B.2** Pricing transparency
- **B.3** Registration

C Manufacturing & Supply

access to medicine FOUNDATION



- **C.1** Overcoming local barriers
- C.2 Ensuring rational use
- **C.3** Responding to shortages
- **C.4** Collaboration to align supply and demand
- **C.5** Supporting vaccine security
- **C.6** Increasing global manufacturing capacity



Questions?



Thank you

jiyer@atmindex.org

www.atmindex.org

Data points – general



- Vaccines revenues
- Number of vaccine dosages sold annually
- Examples of response to market incentives
- Examples of market disincentives
- Vaccine R&D expenditures
- R&D projects technologies
- Vaccine pricing strategy
- Public disclosure pricing strategy and price points
- Policy for filing for registration in Index Countries
- Strategy for responding to stock-outs
- Policy for engaging with purchasers and market shapers
- Policy for considering global health needs
- Examples of assisting manufacturers in Index Countries

Data points – product-specific

access to medicine FOUNDATION

Marketed vaccines:

- Patent information
- Registration in Index Countries
- Adaptations to vaccines
- Adaptations to vaccine packaging and brochures

Pipeline vaccines:

- Phase of development
- Type of development (adaptive/innovative)
- Partnership information
- Access provisions